Toll Free: 1-888-928-9744

Seborrhea - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Seborrhea - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Seborrhea - Pipeline Review, H2 2017, provides an overview of the Seborrhea (Dermatology) pipeline landscape.

Seborrhea is form of skin eczema that mainly affects scalp, ears, face, chest, and folds of skin. Symptoms include skin flakes, red skin, itching and skin lesions. Risk factors include stress or fatigue, skin acne and obesity. Treatment includes antifungal medications. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Seborrhea - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Seborrhea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Seborrhea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 2 respectively.

Seborrhea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Seborrhea (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Seborrhea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Seborrhea (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Seborrhea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Seborrhea (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Seborrhea (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Seborrhea (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Seborrhea - Overview Seborrhea - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Seborrhea - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Seborrhea - Companies Involved in Therapeutics Development Aclaris Therapeutics Inc Amorepacific Corp Biomar Microbial Technologies EpiPharm AG Vyome Biosciences Pvt Ltd Seborrhea - Drug Profiles artemether - Drug Profile Product Description Mechanism Of Action R&D Progress hydrogen peroxide - Drug Profile Product Description Mechanism Of Action R&D Progress IB-07A081 - Drug Profile Product Description Mechanism Of Action R&D Progress IB-07A085 - Drug Profile Product Description Mechanism Of Action R&D Progress ketoconazole - Drug Profile Product Description Mechanism Of Action R&D Progress PAC-14028 - Drug Profile Product Description Mechanism Of Action R&D Progress Seborrhea - Dormant Projects Seborrhea - Discontinued Products Seborrhea - Product Development Milestones Featured News & Press Releases Aug 03, 2017: Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis Jun 13, 2017: Aclaris Therapeutics Announces Issuance of New US Patent For A-101 Topical Solutions May 09, 2017: FDA Accepts Aclaris Therapeutics' New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition Apr 26, 2017: Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution Feb 27, 2017: Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis - a Common Skin Condition Nov 15, 2016: Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition Oct 19, 2016: New Observational Study Demonstrates Patient Impact of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis Mar 17, 2015: Aclaris Therapeutics' Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Seborrhea, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Seborrhea - Pipeline by Aclaris Therapeutics Inc, H2 2017 Seborrhea - Pipeline by Amorepacific Corp, H2 2017 Seborrhea - Pipeline by Biomar Microbial Technologies, H2 2017 Seborrhea - Pipeline by EpiPharm AG, H2 2017 Seborrhea - Pipeline by Vyome Biosciences Pvt Ltd, H2 2017 Seborrhea - Dormant Projects, H2 2017 Seborrhea - Discontinued Products, H2 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify